Core Viewpoint - Nanhua Financial (00619.HK) has signed a memorandum of understanding to establish a joint venture focused on AI-enabled biotechnology, aiming to diversify its business and tap into high-growth sectors such as AI drug development and anti-aging products [1][2] Group 1: Joint Venture Details - The joint venture will be established in mainland China or Hong Kong and will focus on developing an AI drug research platform, AI efficacy prediction services for global beauty clients, disease and aging pipelines, and consumer-facing anti-aging products [1] - The partner company specializes in AI technology for data analysis, molecular mechanism research, and clinical applications [1] Group 2: Strategic Alignment - This collaboration aligns with national and Hong Kong government initiatives to promote strategic emerging industries like AI and biomedicine [2] - The venture aims to integrate financial services with cutting-edge technology, enhancing the company's technological attributes and intrinsic value [2]
南华金融(00619.HK)拟成立合营开发AI药物研发平台及提供相关技术服务